On March 15, 2024, FDA’s medical product centers – CBER, CDER, and CDRH – along with the Office of Combination Products (OCP) published a paper outlining their key areas of focus for the development and use of artificial intelligence (AI) across the medical product life cycle. The paper, entitled “Artificial Intelligence & Medical Products:
Latest Post
More Posts
Framework for the Future of AI: Senator Cassidy Issues White Paper, Seeks Public Feedback
5 Digital Health Issues to Watch at FDA in 2022
FDA Issues Final Guidance on Multiple Function Digital Health Software and Other Devices
Return to Workplace Considerations for Businesses Using AI and IoT Technologies
Return to Workplace Considerations for Businesses Using AI and IoT Technologies
Client Alert: FDA Issues Temporary Guidance on New CARES Act Provision Requiring Certain Device Notifications to CDRH
FDA Issues Updated Guidance on the Regulation of Digital Health Technologies
FDA Outlines Proposed Framework for Regulating Artificial Intelligence Software
FDA Outlines Updated Approach to Regulating Digital Health Technologies
Connect: http://www.cov.com/sdanzis
Subscribe: Subscribe via RSS